- Motley Fool•23 hours ago
From drug pricing to tax reform, here's how Pfizer could be impacted by President Trump's proposals.
High-quality dividend stocks never go out of style for long-term investors, and there is no shortage of stocks with high yields and bright prospects for 2017, from telecommunications companies embracing the digital future to pharmaceutical companies riding the success of new drugs. The pharmaceutical sector is a great place to look for generous dividend payers and few stocks sport yields as high as AbbVie's. The patent expired in December on AbbVie's Humira, the top-selling anti-inflammatory drug on the market. AbbVie's shares returned 20%, including dividends, over the past 52 weeks, while the pharmaceutical sector overall was in the red.
- Investor's Business Daily•2 days ago
Roche, Merck and Pfizer will likely disappoint on 2017 guidance, but AbbVie stock remains a "top pick" for Jefferies analyst Jeffrey Holford.
PFE: Summary for Pfizer, Inc. Common Stock - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
|Day's range||31.66 - 32.12|
|52-week range||28.25 - 37.39|
Trade prices are not sourced from all markets
|PE ratio (TTM)||31.90|
|Dividend & yield||1.28 (4.03%)|
|1y target est||N/A|